Work Here?
Overview
Novoic uses artificial intelligence to analyze spoken language to detect early signs of Alzheimer’s disease. It offers a software-based 10-minute speech test that runs on any smart device and is used by medical institutions, with 50+ centers currently adopting the technology. The company aims to extend access to underserved communities where detection is scarce. Revenue comes from selling the software to healthcare providers. Its AI models are validated through Novoic’s own clinical trials and trained on diverse datasets to improve accuracy and fairness.
About Novoic
Industries
Data & Analytics
Enterprise Software
AI & Machine Learning
Healthcare
Company Size
1-10
Company Stage
Seed
Total Funding
$2.6M
Headquarters
London, United Kingdom
Founded
2019
Get referred to Novoic
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 2026 website says Novoic supports underserved communities across 50+ medical centers.
- 2025 ADNI4 paper expanded Storyteller into large-scale remote screening across diverse populations.
- Novoic now exposes speech processing and biomarkers directly through API, widening enterprise sales.
What critics are saying
- Novoic shows no disclosed 2026 funding; runway risk intensifies before 2027.
- Speech biomarkers face competing vendors; hospitals can standardize on alternatives quickly.
- If ADNI4 or sponsor trials stall, Novoic loses the evidence base supporting adoption.
What makes Novoic unique
- Novoic's Storyteller runs remote, unsupervised speech tests in under ten minutes.
- August 2026 website says 50+ centers use Novoic with ADNI4.
- AMYPRED studies validated biomarker-confirmed preclinical Alzheimer’s speech signals in 2025.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$2.6M
Below
Industry Average
Funded Over
1 Rounds
Industry standards
Company News
Novoic Raises £2 Million Seed Investment for AI-based Speech Analysis to Detect Neurological Diseases Earlier Anthemis Exponential Ventures leads the round, with participation from APEX Ventures and Entrepreneur First LONDON, July 31, 2020 Novoic, a digital biotechnology company developing speech-based AI algorithms for diagnosis and monitoring of health conditions, today announced it has raised £2.0 million in Seed funding […]
Novoic, a digital biotechnology company developing speech-based AI algorithms for diagnosis and monitoring of health conditions, today announced it has raised £2.0 million in Seed funding to scale up its AI research team and advance its clinical programmes, including in early-stage Alzheimer's and Parkinson's disease.
There are no jobs for Novoic right now.
Find jobs on Simplify and start your career today
About Novoic
Industries
Data & Analytics
Enterprise Software
AI & Machine Learning
Healthcare
Company Size
1-10
Company Stage
Seed
Total Funding
$2.6M
Headquarters
London, United Kingdom
Founded
2019
There are no jobs for Novoic right now.
Find jobs on Simplify and start your career today